Von Willebrand Disease Market Report 2026

The von willebrand disease market size has grown strongly in recent years. It will grow from $1.86 billion in 2025 to $1.99 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to improved awareness of inherited bleeding disorders, availability of plasma-derived vwf therapies, expansion of diagnostic testing capabilities, increased hospital-based hematology care, early clinical research in coagulation disorders.

The von willebrand disease market size is expected to see strong growth in the next few years. It will grow to $2.59 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising investments in gene-based therapies, growing adoption of precision medicine approaches, expansion of patient registries and screening programs, increasing demand for long-acting therapies, advancements in recombinant drug development. Major trends in the forecast period include increasing adoption of recombinant von willebrand factor therapies, rising use of personalized treatment protocols, growing focus on early genetic diagnosis, expansion of home-based treatment options, enhanced monitoring of bleeding disorders.

The rising prevalence of bleeding disorders is expected to drive the growth of the von Willebrand disease market in the coming years. Bleeding disorders are a group of medical conditions that impair the body’s ability to form blood clots, leading to prolonged or excessive bleeding. The increase in diagnosed cases is largely due to advancements in medical knowledge and diagnostic tools, which enable healthcare professionals to accurately identify conditions that were previously undetected. Treatment for von Willebrand disease helps patients with bleeding disorders by improving blood clotting, reducing excessive bleeding, and enhancing overall quality of life. For example, in April 2024, according to the World Federation of Hemophilia, a Canada-based government organization, data collection on individuals with von Willebrand disease (VWD) began in February 2023. By December 31, 2023, 999 people with VWD from 45 hemophilia treatment centers (HTCs) across 22 countries had been enrolled in the WBDR. In the same year, aggregated data were collected on 13,343 people with hemophilia (PWH) from 119 HTCs in 44 countries. Therefore, the growing prevalence of bleeding disorders is fueling the expansion of the von Willebrand disease market.

Key companies operating in the von Willebrand disease market are focusing on innovative therapeutics, such as von Willebrand factor (VWF) concentrate, to enhance treatment efficacy, reduce bleeding episodes, and improve patient outcomes. VWF concentrate is a medication used to treat and prevent bleeding in patients with von Willebrand disease, a genetic bleeding disorder caused by a deficiency or dysfunction of the von Willebrand factor. For instance, in April 2024, Octapharma USA Inc., a US-based pharmaceutical company, announced that Wilate received approval from the U.S. Food and Drug Administration (FDA). Wilate is a lyophilized powder solution for intravenous injection used for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children aged six years and older. The FDA’s orphan drug designation provides Wilate with up to seven years of market exclusivity, aimed at encouraging the development of treatments for rare diseases.

In January 2024, Takeda Pharmaceutical Company, a Japan-based pharmaceutical firm, acquired Shire plc. for $62 billion. Through this acquisition, Takeda aims to strengthen its position by expanding its portfolio in rare diseases, plasma-derived therapies, and hematology, including treatments for von Willebrand disease and other bleeding disorders. Shire plc., based in the UK, specializes in rare diseases, including von Willebrand disease.

Major companies operating in the von willebrand disease market are Pfizer Inc., Bayer AG, Sanofi S A, Takeda Pharmaceutical Company Limited, Novo Nordisk A S, CSL Behring, Grifols S A, Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co Ltd, Biotest AG, LFB S A, Bio Products Laboratory Ltd BPL, Octapharma AG, Baxter International Inc, Biogen Inc, Swedish Orphan Biovitrum AB, Roche Holding AG, BioMarin Pharmaceutical Inc, Ferring Pharmaceuticals, Alnylam Pharmaceuticals, Star Therapeutics Inc, Hemab Therapeutics, HEMA Biologics.

North America was the largest region in the von willebrand disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the von willebrand disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the von willebrand disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the von willebrand disease market by increasing costs of imported plasma-derived products, recombinant proteins, biologics manufacturing equipment, and cold-chain logistics services. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported biologics and fractionation technologies, while Asia-Pacific faces higher costs in establishing advanced production facilities. These tariffs contribute to higher treatment costs and reimbursement pressures. However, they are also encouraging regional biologics manufacturing, local plasma collection initiatives, and investments in domestic production capabilities that support long-term supply security.

The von willebrand disease market research report is one of a series of new reports that provides von willebrand disease market statistics, including von willebrand disease industry global market size, regional shares, competitors with a von willebrand disease market share, detailed von willebrand disease market segments, market trends and opportunities, and any further data you may need to thrive in the von willebrand disease industry. This von willebrand disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Von Willebrand disease (VWD) is a genetic bleeding disorder caused by a deficiency or dysfunction of von Willebrand factor (VWF), a protein essential for proper blood clotting. The severity of the disorder depends on both the quantity and functionality of von Willebrand factor present in the blood.

The primary types of von Willebrand disease are type 1, type 2, and type 3. Type 1 is a mild form of the disorder in which an individual has lower-than-normal levels of von Willebrand factor, affecting the blood’s ability to clot properly. Treatments include drugs such as antihemophilic factor, coagulation factor VIII complex, von Willebrand factor, desmopressin acetate, and others, administered according to severity - mild, moderate, or severe. These therapies are delivered through various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, and are utilized by a range of end users, such as hospitals, specialty clinics, homecare providers, and more.

The von willebrand disease market consists of sales of antifibrinolytic drugs, harmonal therapy, and clotting factor concentrates. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.